Assertio Holdings Inc Stock Price, News & Analysis

Assertio Holdings (Nasdaq: ASRT) reported preliminary, unaudited financial results for Q4 and Full Year 2022, highlighting a year-over-year net product sales increase of at least 54% for the fourth quarter and 41% for the full year. The company achieved cash flows from operations of at least $26 million for Q4 and $78 million for the year, reflecting strong commercial execution. Net product sales for Q4 ranged from $49 million to $50 million, while full-year sales ranged from $154 million to $155 million. Assertio will provide more detailed audited results on March 8, 2023.

Assertio Holdings, Inc. (NASDAQ: ASRT), a specialty pharmaceutical company, announced investor meetings scheduled for February 23, 2023, as part of the virtual Third Annual Winter Wonderland Best Ideas Investor Conference. CEO Dan Peisert and CFO Paul Schwichtenberg will host these meetings. Additionally, a group presentation will take place on February 22, 2023, at 9:30 AM ET, accessible via the Investor Relations section on Assertio’s website. For one-on-one meeting scheduling, interested parties can contact the conference hosts via provided email addresses.

Assertio focuses on differentiated pharmaceutical products in neurology, hospital, and pain/inflammation sectors.

Assertio Holdings, Inc. (Nasdaq: ASRT), a specialty pharmaceutical company, announced that CEO Dan Peisert and CFO Paul Schwichtenberg will conduct investor meetings on February 15, 2023, during the SVB Securities Global Biopharma Conference, which will be held virtually.

Investors can schedule one-on-one meetings by contacting their SVB Securities representative or reaching out to Matt Kreps in Investor Relations at Assertio. The company offers a wide range of branded prescription products, focusing on neurology, hospital, and pain and inflammation sectors, and has expanded through licensing, mergers, and acquisitions.

Assertio Holdings, Inc. (Nasdaq: ASRT) announced a $100,000 educational grant to the LGS Foundation to raise awareness about Lennox-Gastaut Syndrome (LGS) and provide educational resources. Assertio recently acquired exclusive rights to SYMPAZAN^® (clobazam) oral film, FDA-approved for treating seizures associated with LGS in patients aged two and older. The company aims to enhance awareness of SYMPAZAN's unique oral film delivery method, which simplifies medication administration for LGS patients. This collaboration signifies Assertio's commitment to improving the lives of those affected by LGS.

Assertio Holdings, Inc. (Nasdaq: ASRT) announced the addition of U.S. Patent No. 11541002 for Sympazan oral film to the FDA's Orange Book, extending patent protection until 2039. This patent is crucial for the treatment of epilepsy with clobazam. The company aims to boost its portfolio through strategic business development, targeting an incremental gross profit increase of $50 million by 2024. Currently, $18 million is secured from recent transactions, including Sympazan. Assertio's focus remains on diversifying its assets and enhancing its market position.

Assertio Holdings announced the grant of restricted stock units (RSUs) and stock options to four newly-hired employees, effective January 3, 2023, totaling 14,804 RSUs and 16,001 options. This initiative, per NASDAQ Listing Rule 5635(c)(4), aims to attract talent. The stock options have an exercise price of $4.17 per share, equal to the company's closing stock price on the grant date, and will vest annually over three years.

Assertio focuses on differentiated pharmaceutical products in neurology, hospital, and pain management.

Assertio Holdings (NASDAQ: ASRT) will conduct one-on-one investor and business development meetings in San Francisco from January 9-11, 2023, coinciding with the annual JP Morgan Healthcare Conference. The meetings aim to discuss investment opportunities and potential partnerships. Interested parties can reach out to Matt Kreps for investor inquiries or Vanessa Fox for business development meetings via the provided contact information. Assertio is focused on expanding its portfolio through acquisitions and licensing of approved products.

Assertio Holdings, Inc. (ASRT) has raised its 2022 full-year net product sales outlook to over $152 million, an increase from the previous forecast of over $141 million. This revision follows strong sales performance in the fourth quarter, with contributions particularly from Indocin and the newly added Sympazan. CEO Dan Peisert noted that net product sales have consistently exceeded expectations throughout the year, driven by better-than-anticipated volume across the product portfolio.

Assertio Holdings, Inc. (Nasdaq: ASRT) reported a 32% increase in net product sales year-over-year for Q3 2022, totaling $34.3 million. Adjusted EBITDA rose 36% to $21.4 million. The company refinanced its debt to lower costs and extend maturity, enhancing financial flexibility. Assertio expects Sympazan to contribute an additional $1 million in sales in Q4. With cash reserves at $64.8 million, the company revised its full-year guidance to anticipate net product sales exceeding $141 million and adjusted EBITDA surpassing $86 million, reflecting positive operational performance.